Engineering the blood: Lipid nanoparticle platforms for ex vivo immune and hematopoietic cell therapies.
- DOI
- 10.1016/j.jconrel.2026.115211
- Published
- 2026 Oct 10
- Container
- Journal of controlled release : official journal of the Controlled Release Society
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jconrel.2026.115211,
title = {Engineering the blood: Lipid nanoparticle platforms for ex vivo immune and hematopoietic cell therapies.},
author = {Byeon Y and Peng N and Oh EB and Kim E and Gu D and Kang H and Badior KE and Chang TS and Kastrup CJ and Lee H},
year = {2026},
journal = {Journal of controlled release : official journal of the Controlled Release Society},
doi = {10.1016/j.jconrel.2026.115211},
url = {https://doi.org/10.1016/j.jconrel.2026.115211}
}RIS
TY - JOUR TI - Engineering the blood: Lipid nanoparticle platforms for ex vivo immune and hematopoietic cell therapies. AU - Byeon Y AU - Peng N AU - Oh EB AU - Kim E AU - Gu D AU - Kang H AU - Badior KE AU - Chang TS AU - Kastrup CJ AU - Lee H PY - 2026 JO - Journal of controlled release : official journal of the Controlled Release Society DO - 10.1016/j.jconrel.2026.115211 UR - https://doi.org/10.1016/j.jconrel.2026.115211 ER -
APA
Y, B., N, P., EB, O., E, K., D, G., H, K., KE, B., TS, C., CJ, K., & H, L. (2026). Engineering the blood: Lipid nanoparticle platforms for ex vivo immune and hematopoietic cell therapies.. Journal of controlled release : official journal of the Controlled Release Society. https://doi.org/10.1016/j.jconrel.2026.115211
Source records
- pubmed · retrieved 2026-09-27T01:12:26.050Z